US 11,918,662 B2
Heterocyclic compounds and imaging agents for imaging huntingtin protein
Longbin Liu, Thousand Oaks, CA (US); Matthew Lee, San Diego, CA (US); Celia Dominguez, Los Angeles, CA (US); Peter David Johnson, Wantage (GB); Catherine Jane Greenaway, Banbury (GB); Kanika Khurana, London (GB); Matthew Robert Mills, Wantage (GB); and Filippo Rota, Bristol (GB)
Assigned to CHDI Foundation, Inc., New York, NY (US)
Filed by CHDI Foundation, Inc., York, NY (US)
Filed on Jun. 10, 2021, as Appl. No. 17/344,582.
Claims priority of provisional application 63/037,751, filed on Jun. 11, 2020.
Prior Publication US 2021/0393812 A1, Dec. 23, 2021
Int. Cl. A61K 51/04 (2006.01); C07B 59/00 (2006.01); C07D 231/12 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/14 (2006.01); C07D 519/00 (2006.01)
CPC A61K 51/0459 (2013.01) [A61K 51/0455 (2013.01); A61K 51/0463 (2013.01); C07B 59/002 (2013.01); C07D 231/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/14 (2013.01); C07D 519/00 (2013.01); C07B 2200/05 (2013.01)] 8 Claims
 
1. A compound of formula:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or an isotopically enriched analog, pharmaceutically acceptable salt, tautomer, stereoisomer, or a mixture of stereoisomers thereof, wherein the compound is labeled with one or more positron-emitting radioactive isotopes selected from 11C, 13N, 15O, and 18F.